Search

The article reports that Onconova Therapeutics and the Leukemia & Lymphoma Society have teamed up for the commercialization of Onconova's myelodysplastic syndrome treatment called Estybon.

The article reports on the approval issued by the U.S. Food and Drug Administration for the use of a five-day regimen of decitabine in patients with myelodysplastic syndromes.

This section offers news briefs concerning clinical trials. A phase 3 randomized international trial found that azacitidine increases the survival rates for patients with high-risk types of myelodysplastic syndromes (MDS). Phase 2 results of a randomized, double-blind, placebo-controlled trial revealed that menopausal vasomotor symptoms such as hot flushes can be treated with Menerba. A phase 3 study showed that rate of recurrence of Kit (CD117)-positive gastrointestinal stromal tumors (GIST) can be reduced by imatinib mesylate.